

## Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia in the ATRA and ATO era

Safaa M. Ramadan,<sup>1,2</sup> Ambra Di Veroli,<sup>1</sup> Agnese Camboni,<sup>3</sup> Massimo Breccia,<sup>4</sup> Anna Paola Iori,<sup>4</sup> Franco Aversa,<sup>5</sup> Luca Cupelli,<sup>6</sup> Cristina Papayannidis,<sup>7</sup> Andrea Bacigalupo,<sup>3</sup> William Arcese,<sup>1</sup> and Francesco Lo-Coco<sup>1,8</sup>

<sup>1</sup>Department of Biopathology, University of Rome 'Tor Vergata', Italy; <sup>2</sup>Department of Medical Oncology, NCI-Cairo University, Egypt; <sup>3</sup>Hematology Division II, BMT Transplant Centre, AUO San Martino, Genoa, Italy; <sup>4</sup>Department of Human Biotechnologies and Hematology, La Sapienza, Rome, Italy; <sup>5</sup>Hematopoietic Stem Cell Transplant Unit, Section of Hematology and Immunology, Department of Clinical and Experimental Medicine, University of Perugia, Italy; <sup>6</sup>Hematology, Sant'Eugenio Hospital, Rome, Italy; <sup>7</sup>Institute of Hematology and Medical Oncology 'Seràgnoli', University of Bologna, Italy; and <sup>8</sup>Laboratorio di Neuro-Oncoematologia, Fondazione Santa Lucia, Rome, Italy

Citation: Ramadan SM, Di Veroli A, Camboni A, Breccia M, Iori AP, Aversa F, Cupelli L, Papayannidis C, Bacigalupo A, Arcese W, and Lo-Coco F. Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia in the ATRA and ATO era. *Haematologica* 2012;97(11):1731-1735. doi:10.3324/haematol.2012.065714

Online Supplementary Table S1. Patients and pre-transplant features.

UPN	Age/sex	1 <sup>st</sup> line therapy	Duration of CR1	2 <sup>nd</sup> line therapy	Salvage therapies 3 <sup>rd</sup> line	4 <sup>th</sup> line	Disease status at SCT	PML/RARA RT-PCR at SCT
UPN1	55/M	AIDA	56	ATRA-AraC-MTZ	-	-	CR2	negative
UPN2	48/M	AIDA	27	ATO	-	-	CR2	negative
UPN3	30/F	AIDA	49	AraC-MTZ	-	-	CR2	negative
UPN4	25/M	AIDA	21	ATO	-	-	CR2	negative
UPN5	19/M	AIDA	14	ATO	-	-	CR2	negative
UPN6	44/F	AIDA	31	ATO	-	-	CR2	negative
UPN7	36/M	AIDA	UNK	UNK	-	-	CR2	negative
UPN8	40/M	AIDA	18	ATRA-AraC-MTZ	AraC- GO	-	CR3	negative
UPN9	41/M	AIDA	42	GO	AraC-MTZ	-	CR3	negative
UPN10	52/M	AIDA	13	ATO	GO -IT (MTX-AraC+PDN)	-	CR3	negative
UPN11	45/M	AIDA	10	GO	ATO-ATRA	-	CR3	negative
UPN12	31/M	AIDA	55	AraC-MTZ-RT	ATO-ATRA-RT	-	CR3	negative
UPN13	16/M	AIDA	61	GO	ATO-ATRA	-	CR3	negative
UPN14	27/F	AIDA	27	AIDA	ATO-IDA	-	CR3	negative
				IT (MTX-AraC-PDN)				
UPN15	38/M	IDA+VP16-AraC	7	AIDA	AIDA	UNK	CR4	negative
UPN16	41/M	AIDA	8	ATO-ATRA-GO	-	-	CR2	positive
UPN17	42/M	AIDA	8	ATO-ATRA-GO	-	-	CR2	positive
UPN18	23/M	AIDA	20	IDA-AraC	-	-	CR2	positive
UPN19	33/M	AIDA	14	UNK	-	-	CR2	positive
UPN20	51/F	AIDA	6	UNK	-	-	CR2	positive
UPN21	22/F	DNR-AraC	44	MTZ-AraC	-	-	CR2	positive
UPN22	37/M	AIDA	7	AraC-MTZ	-	-	CR2	positive
UPN23	18/M	AIDA	24	AIDA	-	-	CR2	positive
UPN24	52/M	AIDA	36	ATO- ATRA	AIDA	-	CR3	positive
UPN25	31/M	AIDA	11	ATO	ATRA-GO	-	CR3	positive
UPN26	46/F	AIDA	10	AraC-MTZ	ATO-ATRA	-	CR3	positive
UPN27	40/F	AIDA	23	AraC-VP	UKN	-	CR3	positive
UPN28	55/M	AIDA	12	ATO	FLU-AraC-IDA-ATRA	DNR-ATRA	CR3	positive
UPN29	51/M	AIDA	41	ATRA-AraC-MTZ-GO-RT	CTX	ATRA-ATO	CR4	positive
UPN30	28/M	AIDA	24	ATO-GO	AraC-MTZ	ATO-ATRA	CR4	positive
UPN31	39/M	AIDA	15	ATRA-AraC-MTZ	GO-ATRA	IT (MTX-AraC-PDN)	CR4	positive
				IT (MTX-AraC-PDN)				

UNK: unknown; DNR: daunorubicin; AraC: cytarabine; GO: gemtuzumab ozogamicin; MTZ: mitoxantrone; ATO: arsenic trioxide; RT: radiotherapy; IT: intrathecal therapy; VP16: etoposide; FLU: fludarabine; IDA: idarubicin; DNR: daunorubicin; SCT: stem cell transplant.

**Online Supplementary Table S2.** Outcome of transplanted patients according to both the number of remission and RT-PCR of MPL/RARA status at time of transplant.

CR number and RT-PCR status at transplant	N. of patients	Outcome Dead (cause of death) Alive Lost to follow up
CR2 and RT-PCR-negative	7	2 dead (due to relapse) 4 alive 1 lost to follow up while in CR (at 7 months)
≥CR3 and RT-PCR-negative	8	4 dead (2 due to relapse, 2 of transplant-related complications) 4 alive in CR
CR2 and RT-PCR-positive	8	4 dead (2 due to relapse, 2 of transplant-related complications) 3 alive in CR 1 lost to follow up in CR (at 4 months)
≥CR3 and RT-PCR-positive	8	7 dead (5 due to relapse, 2 of transplant-related complications) 1 alive after haploidentical transplant